HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nestle Increases Health Care Investment With Galderma Control

This article was originally published in The Tan Sheet

Executive Summary

Galderma will be the “foundation” of a new division to be called Nestle Skin Health SA, said Nestle Chairman Peter Brake-Letmathe. L’Oreal will give Nestle its 50% stake in Galderma and $4.6 billion in cash to buy back 8% of its own stock from Nestle.

You may also be interested in...

Prospect Of L’Oreal Share Buyback Excites Investors

Sanofi SA has the cash to buy back about $12 billion worth of shares in its company that are currently owned by French beauty firm L’Oreal, if those shares were up for sale, Sanofi CEO Viehbacher says during Sept. 13 conference. L’Oreal CEO Agon suggested in recent earnings call that his firm could seek cash for future deals through the sale of its 9% stake in Sanofi.

Nestle China JV Backs Nutritional And Rx Botanical Development

Nestle Health Science and Chi-Med’s joint venture Nutrition Science Partners creates an opportunity to develop and commercialize scientifically validated botanical nutritionals and drugs, based in part on Chi-Med’s traditional Chinese medicine library of 1,200 plants and 50,000 extracts.

QHC study

FDA plans to conduct a study to "further explore" the use of report card grading schemes in qualified health claims (QHCs), according to a notice published in the Federal Register May 22. The study builds off previous research that found report card schemes were effective in conveying the "intended ordering of scientific certainty," but led consumers to be more certain of "B" and "C" claims than claims of higher scientific certainty, which did not receive a grade (1"The Tan Sheet" Oct. 10, 2005, p. 7). The proposed study will attempt to correct for "misperceptions" observed in the previous study and will position unqualified claims as "A" grade claims. Additionally, the study will use actual health claims and variants of these claims rather than hypothetical claims. Green tea and cancer, coronary heart disease and consumption of monounsaturated fatty acids from olive oil as well as omega-3 fatty acids and CHD claims will be used. An earlier version of the study was proposed in March 2005 (2"The Tan Sheet" April 4, 2005, In Brief)...


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts